Opicapone

Drug Profile

Opicapone

Alternative Names: [14C]-BIA 9-1067; BIA-91067; Ongentys; ONO-2370

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BIAL
  • Developer BIAL; Neurocrine Biosciences; Ono Pharmaceutical
  • Class Antiparkinsonians
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in Japan (PO, Tablet)
  • 01 Nov 2017 Ono Pharmaceutical completes a phase I trial in Healthy volunteers in Japan (PO) (JapicCTI-173583)
  • 27 Apr 2017 Bial completes a phase I trial in Healthy volunteers in United Kingdom (NCT03119194)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top